BCYC
NASDAQ
$4.16
Bicycle Therapeutics Plc (BCYC)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $12.62 (+203.37%)
Market Cap
$294M
P/B Ratio
0.53
Revenue 5Y CAGR
+41.82%
FCF 5Y CAGR
+33.73%
Price Chart
Valuation
Market Cap$294M
P/S4.64
P/B0.53
Profitability
Total Revenue (TTM)$63M
Gross Profit (TTM)-$155M
EBITDA-$236M
Operating Margin-7382%
EPS-$3.16
Financial Health
Free Cash Flow Yield-78.76%
Growth & Risk
EPS 5Y CAGR+11.06%
Revenue 5Y CAGR+41.82%
FCF 5Y CAGR+33.73%
Beta (5Y)1.26
Sharpe Ratio-1.10